Apnimed旗下AD109在三期试验中总体耐受性良好,口干、失眠、恶心为常见不良事件

美股速递
Jul 14

Apnimed Inc. 宣布,其候选药物AD109在关键性三期临床试验中展现出总体良好的耐受性。数据显示,治疗过程中报告的不良事件大多为轻度至中度。其中,口干、失眠和恶心是最为常见的副作用。这些发现对于评估该药物的整体安全性特征至关重要。公司表示,详细的数据将在未来的医学会议上进一步公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10